Volume | 112,990 |
|
|||||
News | - | ||||||
Day High | 1.75 | Low High |
|||||
Day Low | 1.58 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioSig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.58 | 1.58 | 1.75 | 1.65 | 1.61 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
798 | 112,990 | $ 1.69 | $ 190,492 | - | 0.2619 - 16.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:12:07 | 1 | $ 1.65 | USD |
BioSig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.59M | 9.33M | - | 18k | -29.05M | -3.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioSig Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.30 | 1.75 | 1.23 | 1.48 | 114,410 | 0.35 | 26.92% |
1 Month | 1.56 | 2.00 | 1.2099 | 1.56 | 160,485 | 0.09 | 5.77% |
3 Months | 0.3068 | 2.98 | 0.285 | 1.40 | 1,204,525 | 1.34 | 437.81% |
6 Months | 3.655 | 4.999 | 0.2619 | 1.69 | 761,307 | -2.01 | -54.86% |
1 Year | 13.60 | 16.50 | 0.2619 | 5.37 | 647,046 | -11.95 | -87.87% |
3 Years | 33.90 | 45.80 | 0.2619 | 10.56 | 412,957 | -32.25 | -95.13% |
5 Years | 84.60 | 124.30 | 0.2619 | 33.23 | 416,006 | -82.95 | -98.05% |
BioSig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |